Table 1.
Demographics and characteristics of study participants.
| Factor | Non-hospitalized, n (%) [N = 4,077 (88.3%)] |
Hospitalized, n (%) [N = 541 (11.7%)] |
Total, n (%) N = 4,618 |
|---|---|---|---|
| Age (mean ± SD) | 29 ± 17.1 | 51.6 ± 20.4 | 32 ± 18.8 |
| < 18 years | 1,227 (30.1%) | 27 (5.0%) | 1,254 (27.2%) |
| 19–44 years | 2,068 (50.7%) | 166 (30.7%) | 2,234 (48.4%) |
| > 45 years | 779 (19.1%) | 348 (64.3%) | 1,127 (24.4%) |
| Missing | 3 (0.1%) | 0 (0.0%) | 3 (0.1%) |
| Sex, n (%) | |||
| Male | 2,085 (50.1%) | 294 (54.3%) | 2,379 (51.5%) |
| Female | 1,990 (48.8%) | 233 (43.1%) | 2,223 (48.1%) |
| Missing | 2 (0.04%) | 14 (2.6%) | 16 (0.3%) |
| Nationality, n (%) | |||
| Middle Eastern | 2,671 (65.5%) | 293 (54.2%) | 2,964 (64.2%) |
| Asian | 901 (22.1%) | 199 (36.8%) | 1,100 (23.8%) |
| African | 375 (9.2%) | 45 (8.3%) | 420 (9.1%) |
| European | 26 (0.6%) | 2 (0.4%) | 28 (0.6%) |
| American | 12 (0.3%) | 2 (0.4%) | 14 (0.3%) |
| Missing | 92 (2.1%) | 0 (0.0%) | 92 (2.0%) |
| Vaccination status, n (%) | |||
| Partially vaccinated | 162 (4.0%) | 45 (8.3%) | 207 (4.5%) |
| Fully vaccinated | 1,812 (44.4%) | 85 (15.7%) | 1,897 (41.1%) |
| Unvaccinated | 1,317 (32.3%) | 382 (70.6%) | 1,699 (36.8%) |
| Missing | 786 (19.3%) | 29 (5.4%) | 815 (17.6%) |
| Vaccine type, n (%) | |||
| BBIBP-CorV | 1,606 (58.1%) | 120 (22.2%) | 1,726 (37.4%) |
| BNT162b2 | 200 (7.2%) | 8 (1.5%) | 208 (4.5%) |
| Others† | 32 (1.4%) | 31 (5.7%) | 32 (0.7%) |
| Missing | 922 (33.4%) | 382 (70.6%) | 953 (20.6%) |
| Variant of concern, n (%) | |||
| Delta | 3,410 (83.6%) | 475 (87.8%) | 3885 (84.1%) |
| Omicron | 667 (16.4%) | 66 (12.2%) | 733 (15.9%) |
Missing variables were not included in subsequent analyses.
†This includes other vaccine types such as ChAdOx1, JNJ-78436735, and Gam-COVID-Vac.